Liquidia Corporation (NASDAQ:LQDA) announced Thursday a lawsuit challenging the recent FDA decision to grant a three-year ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in ...

United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high ...

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Total Tyvaso revenues grew by 19 percent to $415.9 million in the fourth quarter of 2024, compared to $350.6 million in the fourth quarter of 2023. This growth was primarily driven by growth in ...